Edition:
United States

Peregrine Pharmaceuticals Inc (PPHM.O)

PPHM.O on Consolidated Issue listed on NASDAQ Capital Market

0.37USD
26 Jul 2016
Change (% chg)

-- (--)
Prev Close
$0.37
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,441,039
52-wk High
$1.33
52-wk Low
$0.29

Latest Key Developments (Source: Significant Developments)

Peregrine Pharmaceuticals Q4 loss per share $0.05
Thursday, 14 Jul 2016 04:05pm EDT 

Peregrine Pharmaceuticals Inc : Peregrine pharmaceuticals reports financial results for quarter and fiscal year ended april 30, 2016 and recent developments . Q4 loss per share $0.05 . Q4 revenue $18.78 million versus i/b/e/s view $15.8 million . Q4 earnings per share view $-0.03 -- Thomson Reuters I/B/E/S . Peregrine pharmaceuticals inc says analysis of data from sunrise phase iii trial ongoing with new clinical trials expected to commence late 2016 to early 2017 .Says Growing Biomanufacturing Demand Prompts Plans For Third Manufacturing Facility Expected To Be Commissioned By Mid 2017.  Full Article

Peregrine Pharmaceuticals declares quarterly dividend
Monday, 7 Dec 2015 04:00pm EST 

Peregrine Pharmaceuticals:Declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock.The quarterly dividend on the Series E Preferred Stock is payable on January 4, 2016 to holders of record at the close of business on December 18, 2015.The quarterly dividend payment on the Series E Preferred Stock will be $0.65625 per share.  Full Article

Peregrine Pharmaceuticals Inc declares quarterly dividend on its Series E Convertible preferred stock
Tuesday, 8 Sep 2015 04:05pm EDT 

Peregrine Pharmaceuticals Inc:Declares quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock.Payable on Oct. 1 to holders of record at the close of business on Sept. 18.Quarterly dividend payment on the Series E Preferred Stock will be $0.65625 per share.  Full Article

Peregrine Pharmaceuticals Inc data presented at AACR demonstrate synergistic anti-tumor effects of peregrine pharmaceuticals' phosphatidylserine (PS)
Tuesday, 21 Apr 2015 08:00am EDT 

Peregrine Pharmaceuticals Inc:Says presentation of data from preclinical studies demonstrating combination of phosphatidylserine (PS) blockade with anti-PD-1 or anti-CTLA-4 immune checkpoint inhibitors promoted strong, localized and enhanced efficacy in models of melanoma and breast cancer.Says these data were presented at 106th Annual Meeting of the American Association for Cancer Research (AACR) being held in Philadelphia, Pennsylvania from April 18-22, 2015.Says Peregrine's lead PS-blocking antibody, bavituximab, is currently being evaluated in second-line non-small cell lung cancer (NSCLC) in Phase III clinical trial named Sunrise.  Full Article

Peregrine Pharmaceuticals declares quarterly dividend on its Series E Convertible Preferred Stock
Tuesday, 10 Mar 2015 04:00pm EDT 

Peregrine Pharmaceuticals Inc:Declared a quarterly cash dividend payment on the Company's 10.50 pct Series E Convertible Preferred Stock.The quarterly dividend on the Series E Preferred Stock is payable on April 1, to holders of record at the close of business on March 20.  Full Article

Peregrine Pharmaceuticals Inc reaffirms FY 2015 guidance - Conference Call
Wednesday, 10 Dec 2014 04:30pm EST 

Peregrine Pharmaceuticals Inc:Anticipates contract manufacturing revenue will be between $19 million and $23 million for FY 2015, in line with previous guidance.FY 2015 revenue of $23 million - Thomson Reuters I/B/E/S.  Full Article

Peregrine Pharmaceuticals declares quarterly dividend on Series E convertible preferred stock
Tuesday, 9 Dec 2014 04:00pm EST 

Peregrine Pharmaceuticals:Declares a quarterly cash dividend payment on company's 10.50 pct Series E Convertible Preferred Stock.Payable on Jan. 02, 2015 to holders of record at the close of business on Dec. 19.Quarterly dividend payment on the Series E Preferred Stock will be $0.65625 per share.  Full Article

Peregrine Pharmaceuticals, Inc reaffirms FY 2015 guidance
Tuesday, 9 Sep 2014 04:00pm EDT 

Peregrine Pharmaceuticals, Inc:Expects contract manufacturing revenue for FY 2015 to be between $19 and $23 million.  Full Article

Peregrine Pharmaceuticals Inc declares quarterly dividend on its series E convertible preferred stock
Monday, 8 Sep 2014 04:00pm EDT 

Peregrine Pharmaceuticals Inc:Declares quarterly cash dividend payment on company's 10.50 pct Series E Convertible Preferred Stock.Payable on Oct. 01 to holders of record on Sept. 19.  Full Article

Peregrine Pharmaceuticals Inc announces preclinical data shows combination of Peregrine Pharmaceuticals' PS-Targeting Antibodies and Anti-PD-1 Antibodies Significantly Reduce Breast Cancer Progression
Monday, 11 Aug 2014 08:00am EDT 

Peregrine Pharmaceuticals Inc:Says preclinical data further validating potent immune-stimulatory mechanism of its phosphatidylserine (PS)-targeting immuno-oncology platform.Results show that combination of PS-targeting antibody equivalent to bavituximab administered with an anti-PD-1 antibody displayed statistically significant tumor growth suppression.Says while also demonstrating significant increase in tumor-fighting T-cells into tumor microenvironment compared to anti-PD-1 antibody treatment alone in immune competent animal model of breast cancer.Bavituximab is currently being evaluated in second-line non-small cell lung cancer (NSCLC) as part of the SUNRISE pivotal Phase III clinical trial.Says these data further validate that blocking the immunosuppressive effects of PS facilitate an increase in tumor-fighting T-cells, and that the combination with PD-1 then allows for a more effective anti-tumor T-cell response.  Full Article

BRIEF-Peregrine Pharmaceuticals Q4 loss per share $0.05

* Peregrine pharmaceuticals reports financial results for quarter and fiscal year ended april 30, 2016 and recent developments